Ofloxacin Tablet, Coated
NDC 75834-199
Product Information
Ofloxacin is a ANDA-approved product labeled by Nivagen Pharmaceuticals, Inc.. This medication is used to treat eye infections. It is supplied as a yellow tablet, coated for oral administration. This product entry covers the primary NDC 75834-199 and 3 associated package configurations. This profile includes active and inactive ingredient UNII references and FDA labeling data.
Primary Identification
Clinical Specifications
Labeler & Regulatory Data
Marketing Timeline
Product Characteristics
C213
Code Structure Chart
Product Details
What is NDC 75834-199?
What are the uses of this product?
What are Active Ingredients of this product?
- OFLOXACIN 200 mg/1 - A synthetic fluoroquinolone antibacterial agent that inhibits the supercoiling activity of bacterial DNA GYRASE, halting DNA REPLICATION.
Which are the associated UNII Codes?
The UNII codes for the active ingredients in this product are:
- OFLOXACIN (UNII: A4P49JAZ9H)
- OFLOXACIN (UNII: A4P49JAZ9H) (Active Moiety)
Which are the Inactive Ingredients associated UNII Codes?
The inactive ingredients are all the component of a medicinal product OTHER than the active ingredient(s). The acronym "UNII" stands for “Unique Ingredient Identifier” and is used to identify each inactive ingredient present in a product. The UNII codes for the inactive ingredients in this product are:
- LACTOSE MONOHYDRATE (UNII: EWQ57Q8I5X)
- STARCH, CORN (UNII: O8232NY3SJ)
- HYDROXYPROPYL CELLULOSE (1600000 WAMW) (UNII: RFW2ET671P)
- TALC (UNII: 7SEV7J4R1U)
- MAGNESIUM STEARATE (UNII: 70097M6I30)
- POLYETHYLENE GLYCOL 400 (UNII: B697894SGQ)
- SODIUM STARCH GLYCOLATE TYPE A POTATO (UNII: 5856J3G2A2)
- TITANIUM DIOXIDE (UNII: 15FIX9V2JP)
- FERRIC OXIDE YELLOW (UNII: EX438O2MRT)
What is the NDC to RxNorm Crosswalk for this product?
- RxCUI: 198048 - ofloxacin 200 MG Oral Tablet
- RxCUI: 198049 - ofloxacin 300 MG Oral Tablet
- RxCUI: 198050 - ofloxacin 400 MG Oral Tablet
Which are the Pharmacologic Classes of this product?
* Please review the full disclaimer at the bottom of this page.